![Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy](https://www.tandfonline.com/cms/asset/016edad4-7d89-4255-9d87-be899be2a145/koni_a_2184130_f0005_oc.jpg)
Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
![Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2009.27.3524/asset/images/zlj9991001940003.jpeg)
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
![Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances](https://www.science.org/cms/10.1126/sciadv.abq4617/asset/09aac9bd-08ef-4ec0-8164-651caa59479d/assets/images/large/sciadv.abq4617-f3.jpg)
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances
![The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma - ScienceDirect The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804911000864-gr3.jpg)
The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma - ScienceDirect
![PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/61dfb3a5ee37540ef03aaa30a65508f621b16f2b/4-Table1-1.png)
PDF] Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study | Semantic Scholar
Treatment and management of newly diagnosed patients with high-risk neuroblastoma (not patients currently registered on HR-NBL-1
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SI
![Forest plot of comparison: 1 Rapid COJEC versus standard induction,... | Download Scientific Diagram Forest plot of comparison: 1 Rapid COJEC versus standard induction,... | Download Scientific Diagram](https://www.researchgate.net/publication/277086302/figure/fig1/AS:289342846193667@1445996118096/Forest-plot-of-comparison-1-Rapid-COJEC-versus-standard-induction-outcome-11-Complete.png)
Forest plot of comparison: 1 Rapid COJEC versus standard induction,... | Download Scientific Diagram
![Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/937ec2c5-ef03-442b-ae9a-0722707484ec/gr1.jpg)
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR - Annals of Oncology
![High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy | Scientific Reports High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-023-31805-3/MediaObjects/41598_2023_31805_Fig1_HTML.png)
High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy | Scientific Reports
![Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/a358d0a1-4ba1-4ab7-a820-e11b213aaf3e/gr1.jpg)
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology
![Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study | Semantic Scholar Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e545787e1079eab546e6b0c6503a40e01ed97107/3-Figure1-1.png)
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study | Semantic Scholar
![Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | bioRxiv Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2022/04/02/2022.04.01.486670/F4.large.jpg)
Clinically-relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | bioRxiv
![Schematic overview of therapy on SIOPEN/HR-NBL-1 and COG A3973. Rapid... | Download Scientific Diagram Schematic overview of therapy on SIOPEN/HR-NBL-1 and COG A3973. Rapid... | Download Scientific Diagram](https://www.researchgate.net/publication/320003722/figure/fig2/AS:941397741953026@1601458120318/Schematic-overview-of-therapy-on-SIOPEN-HR-NBL-1-and-COG-A3973-Rapid-COJEC-cycles-given.gif)
Schematic overview of therapy on SIOPEN/HR-NBL-1 and COG A3973. Rapid... | Download Scientific Diagram
![Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2009.27.3524/asset/images/zlj9991001940002.jpeg)
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study | Journal of Clinical Oncology
![Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance | Science Advances](https://www.science.org/cms/10.1126/sciadv.abq4617/asset/48d3e038-217c-4fbf-a0e7-989d9940e5ec/assets/images/large/sciadv.abq4617-f4.jpg)